Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

NCT04333147 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2916

Enrollment

INDUSTRY

Sponsor class

Stopped Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: Otilimab (GSK3196165)
DRUG: csDMARD(s)

Sponsor

GlaxoSmithKline

Collaborators

[object Object]